Close Menu

NEW YORK – Machine learning diagnostic firm Prevencio announced Tuesday it is collaborating with Seattle Children's Research Institute to develop a blood test for Kawasaki disease.

The institute will provide Prevencio with blood samples and the firm will use its HART AI platform to develop a blood test for the disease. Under the agreement, Prevencio will retain exclusive global rights to the test. The firm will use its laboratory partner Myriad RBM to measure proteins in the blood samples.

Additional terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.